Abstract 93P
Background
New predictive biomarkers for cetuximab-resistance for patients with RAS wild-type colorectal liver metastases (CRLM).
Methods
216 patients with initially unresectable liver-limited RAS wild-type CRLM were identified from previous clinical studies. Among these patients, 103 patients received chemotherapy (mFOLFOX6 or FOLFIRI) plus cetuximab, and 113 received chemotherapy alone as first-line treatment. Next-generation sequencing of primary tumors was done for single nucleotide polymorphism according to custom panel. The patients receiving cetuximab-based chemotherapy were divided into two groups: one group was cetuximab-resistant group and the other group was cetuximab-sensitive group. Potential predictive biomarkers were determined by “random forest" machine learning.
Results
Ten potential predictive genes, namely RET, PTPN11, FLT3, AKT1, ACTN4, ERBB4, FGFR3, MDC1, CUL9, and ZNF462, were identified. In the cohort of cetuximab-based chemotherapy, patients with all-wild-type genes had markedly improved median progression-free survival (12.0 vs. 4.0 months, P < 0.0001) and overall survival (37.0 VS. 24.0 months, P < 0.0001) compared with those with gene mutation; In the cohort of at-least-one gene mutation, patients receiving chemotherapy alone had comparable median PFS (4.0 VS. 4.0 months, P = 0.9498). Moreover, mutated are more common in patients with right-sided colon cancer.
Conclusions
Ten new predictive mutations help to refine the selection of RAS and BRAF wild-type metastatic colorectal cancer patients candidates for anti-EGFRs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract